Retrieve available abstracts of 49 articles: HTML format
Single Articles
June 2025
ABBATE A Heart failure with preserved ejection fraction: how far we've come - a brief
report from two outstanding educational events.
J Cardiovasc Pharmacol. 2025 Jun 27. doi: 10.1097/FJC.0000000000001733. PubMed
WU Y, Song M, Chen W, Liang F, et al miR-132 inhibition improves cardiac remodeling and function in a two-hit mouse
model of heart failure with a preserved ejection fraction.
J Cardiovasc Pharmacol. 2025 Jun 18. doi: 10.1097/FJC.0000000000001729. PubMedAbstract available
May 2025
ZHANG J, Chen X, Wan C Aerobic exercise rehabilitation training alleviates skeletal muscle atrophy
caused by heart failure in mice through the SIRT1/PGC-1alpha pathway.
J Cardiovasc Pharmacol. 2025 May 28. doi: 10.1097/FJC.0000000000001722. PubMedAbstract available
YAMASHITA I, Fujisaki T, Romeo FJ, Sueta D, et al Comparing the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors Among
Nonolder and Older Patients: A Systematic Review and Meta-Analysis.
J Cardiovasc Pharmacol. 2025;85:329-337. PubMedAbstract available
April 2025
CHEN C, Qin X, Cao Y, Qing L, et al Flavin adenine dinucleotide ameliorates pressure overload-induced heart failure
by activating the short-chain acyl-CoA dehydrogenase.
J Cardiovasc Pharmacol. 2025 Apr 8. doi: 10.1097/FJC.0000000000001698. PubMedAbstract available
March 2025
BIONDI-ZOCCAI G, Galli M, Booz GW Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction,
Erratum.
J Cardiovasc Pharmacol. 2025;85:238. PubMed
February 2025
GALATI G, Germanova O Mineralocorticoid receptor antagonists in end-stage renal disease under renal
replacement therapies: bridging the gap between cardiovascular and systemic
benefit, from heart failure to myocardial infarction.
J Cardiovasc Pharmacol. 2025 Feb 6. doi: 10.1097/FJC.0000000000001677. PubMed
January 2025
DIMITRIADIS K, Pitsiori D, Alexiou P, Pyrpyris N, et al Modulating Sympathetic Nervous System With the Use of SGLT2 Inhibitors: Where
There Is Smoke, There Is Fire?
J Cardiovasc Pharmacol. 2025;85:12-20. PubMedAbstract available
December 2024
KEFER E, Gulbis B, Weeks P Comparison of Urine Output Response of Intravenous Bumetanide and Furosemide in
Acute Decompensated Heart Failure: an observational analysis.
J Cardiovasc Pharmacol. 2024 Dec 5. doi: 10.1097/FJC.0000000000001658. PubMedAbstract available
November 2024
DENICOLAI M, Morello M, Golino M, Corna G, et al Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial
Infarction Across the Spectrum of Coronary Artery Disease Complexity.
J Cardiovasc Pharmacol. 2024 Nov 12. doi: 10.1097/FJC.0000000000001652. PubMedAbstract available
September 2024
RYUNO Y, Kobayashi JI, Fujimoto Y, Dotare T, et al Effect of an Enteral Formula Enriched with omega-3 Fatty Acids, Carnitine, and
Vitamin D on Body Weight, Heart Weight, and Blood Biochemical Parameters in a
Dahl Rat Heart Failure Model.
J Cardiovasc Pharmacol. 2024 Sep 26. doi: 10.1097/FJC.0000000000001637. PubMedAbstract available
BIONDI-ZOCCAI G, Galli M, Booz GW Finerenone Proves Beneficial for Heart Failure with Preserved Ejection Fraction.
J Cardiovasc Pharmacol. 2024 Sep 26. doi: 10.1097/FJC.0000000000001636. PubMed
BIONDI-ZOCCAI G, Frati G, Peruzzi M, Booz GW, et al Empagliflozin: Primus Inter Pares Among Sodium-Glucose Cotransporter-2
Inhibitors?
J Cardiovasc Pharmacol. 2024;84:271-275. PubMedAbstract available
HAJIQASEMI M, Ebrahimzade M, Ghelichkhan ZA, Huang X, et al Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review.
J Cardiovasc Pharmacol. 2024;84:276-288. PubMedAbstract available
August 2024
HENSON BD, Bale-Neary CA, Mecaskey R, Gbujie O, et al SGLT2 Inhibitors, Malnutrition, Cachexia, and Survival in Heart Failure Patients
with a History of Anthracycline Treatment.
J Cardiovasc Pharmacol. 2024 Aug 7. doi: 10.1097/FJC.0000000000001620. PubMedAbstract available
GIBSON CM, Beard MM, Escano AK, Good BL, et al Metolazone vs chlorothiazide in acute heart failure patients with diuretic
resistance and renal dysfunction: a retrospective cohort study.
J Cardiovasc Pharmacol. 2024 Aug 7. doi: 10.1097/FJC.0000000000001623. PubMedAbstract available
July 2024
LINGYAN Z, Zijia H, Ya Z, Ying Z, et al Cardiovascular outcomes of SGLT-2 Inhibitors Across BMI Spectrum in Heart Failure
Patients: An Updated Systematic Review and Meta-Analysis.
J Cardiovasc Pharmacol. 2024 Jul 8. doi: 10.1097/FJC.0000000000001610. PubMedAbstract available
ZHANG X, Sun G, Li Z, Gao W, et al Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Acute
Myocardial Infarction With or Without Type 2 Diabetes: A Systematic Review and
Meta-analysis.
J Cardiovasc Pharmacol. 2024;84:18-25. PubMedAbstract available
LIU TH, Hsieh RJ, Chen HH, Kuo TJ, et al Propranolol Alleviates Cardiac Injury After Acute Catecholamine Infusion Through
p38-MAPK Pathways.
J Cardiovasc Pharmacol. 2024;84:110-117. PubMedAbstract available
May 2024
HOU B, Yu D, Bai H, Du X, et al Research progress of miRNA in heart failure: prediction and treatment.
J Cardiovasc Pharmacol. 2024 May 3. doi: 10.1097/FJC.0000000000001588. PubMedAbstract available
April 2024
BARBIERO R, Pennella B, Bonaventura A The long-standing search for albumin placement in acute heart failure.
J Cardiovasc Pharmacol. 2024 Apr 24. doi: 10.1097/FJC.0000000000001580. PubMed
KAKZANOV Y, Sevilya Z, Goldman A, Cipok M, et al The Effect of SGLT2 Inhibitor Therapy on Endothelial Progenitor Cell Function in
Patients with Heart Failure.
J Cardiovasc Pharmacol. 2024 Apr 24. doi: 10.1097/FJC.0000000000001581. PubMedAbstract available
POLLESELLO P Repetitive treatments with inotropes in advanced heart failure.
J Cardiovasc Pharmacol. 2024 Apr 2. doi: 10.1097/FJC.0000000000001569. PubMed
The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A
Systematic Review and Meta-Analysis of Randomized Controlled Trials Erratum.
J Cardiovasc Pharmacol. 2024;83:359. PubMed
March 2024
ZHANG X, Wang Z, Zhang L, Zhao X, et al Comparative effectiveness and safety of intermittent, repeated or continuous use
of levosimendan, milrinone, or dobutamine in patients with advanced heart
failure: a network and single-arm meta-analysis.
J Cardiovasc Pharmacol. 2024 Mar 25. doi: 10.1097/FJC.0000000000001561. PubMedAbstract available
ZOHORI BAHRAMI HS, Hasselbalch RB, Soholm H, Thomsen JH, et al First-in-man trial of beta3-adrenoceptor agonist treatment in chronic heart failure
- impact on diastolic function.
J Cardiovasc Pharmacol. 2024 Mar 5. doi: 10.1097/FJC.0000000000001545. PubMedAbstract available
January 2024
HUANG Y, Zhou H, Fang C, Ma L, et al Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for
Patients With Heart Failure in China.
J Cardiovasc Pharmacol. 2024;83:86-92. PubMedAbstract available
December 2023
SCOMA CB, Lee DH, Money D, Eichelberger G, et al The Impact of Midodrine On Guideline-Directed Medical Therapy in Patients
Admitted with Systolic Heart Failure.
J Cardiovasc Pharmacol. 2023 Dec 21. doi: 10.1097/FJC.0000000000001532. PubMedAbstract available
November 2023
SILVETTI S, Pollesello P, Belletti A Repeated levosimendan infusions in the management of advanced heart failure:
review of the evidence and meta-analysis of the effect on mortality.
J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001506. PubMedAbstract available
SUN Q, Cui W, Zhang X, Tian Y, et al A Systematic Review and Meta-analysis of Renin-angiotensin Inhibitors and
Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial
Fibrillation Ablation.
J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001517. PubMedAbstract available
LAI M, Lam JC, Radosevich JJ, Patanwala AE, et al Levels of Albumin and Impact on Loop Diuretic and Albumin Co-administration in
Heart Failure (LILAC-HF).
J Cardiovasc Pharmacol. 2023 Nov 17. doi: 10.1097/FJC.0000000000001513. PubMedAbstract available
KOMMU S The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A
Systematic Review and Meta-Analysis of Randomized Controlled Trials.
J Cardiovasc Pharmacol. 2023 Nov 15. doi: 10.1097/FJC.0000000000001511. PubMedAbstract available
ZHANG X, Wang N, Fu P, An Y, et al Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction
Remodeling and Dysfunction by Elevating beta-Hydroxybutyrate-activated Citrate
Synthase.
J Cardiovasc Pharmacol. 2023;82:375-388. PubMedAbstract available
October 2023
CANTRELL AC, Zeng H, Chen JX The therapeutic potential of targeting ferroptosis in the treatment of
mitochondrial cardiomyopathies and heart failure.
J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001496. PubMedAbstract available
JAFREE E, Del Buono MG, Canada JM, Carbone S, et al Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure.
J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001497. PubMedAbstract available
CAMILLI M, Ballacci F, Giordano F, Minotti G, et al Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with
Heart Failure in China: a new pillar in our pockets, but at what price?
J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001498. PubMedAbstract available
September 2023
BUONPANE A, Biondi-Zoccai G, Versaci F Molecular insights on ischemic heart failure: from core genes to hearts.
J Cardiovasc Pharmacol. 2023 Sep 26. doi: 10.1097/FJC.0000000000001486. PubMed
LIN L, Zicheng L, Shaohua G Post-acute myocardial infarction heart failure core genes and relevant signaling
pathways.
J Cardiovasc Pharmacol. 2023 Sep 6. doi: 10.1097/FJC.0000000000001481. PubMedAbstract available
BROCKMOLLER J, Ivanoski S, Hundack L, Blohm JH, et al Clinical and hemodynamic improvement in pulmonary hypertension after switching to
sacubitril/valsartan in heart failure patients with preserved ejection fraction.
J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001477. PubMedAbstract available
PITT B, Rosenson RS Statins in patients with established heart failure: Time for reflection.
J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001475. PubMed
July 2023
PARK S, Chang J, Hong SP, Jin ES, et al Impact of Trimetazidine on the Incident Heart Failure Following Coronary Artery
Revascularization.
J Cardiovasc Pharmacol. 2023 Jul 11. doi: 10.1097/FJC.0000000000001453. PubMedAbstract available
June 2023
HU WS, Lin CL Angiotensin receptor-neprilysin inhibitor versus renin-angiotensin system
inhibitor for dementia risk in patients with heart failure.
J Cardiovasc Pharmacol. 2023 Jun 30. doi: 10.1097/FJC.0000000000001451. PubMedAbstract available
AHMAD F, Karim A, Khan J, Qaisar R, et al Statin therapy induces gut leakage and neuromuscular disjunction in patients with
chronic heart failure.
J Cardiovasc Pharmacol. 2023 Jun 27. doi: 10.1097/FJC.0000000000001445. PubMedAbstract available
MANILALL A, Mokotedi L, Gunter S, Le Roux R, et al Tumor Necrosis Factor-alpha Mediates Inflammation-induced Early-Stage Left
Ventricular Systolic Dysfunction.
J Cardiovasc Pharmacol. 2023;81:411-422. PubMedAbstract available
May 2023
AUGUSTIN N, Alvarez C, Kluger J The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature
Review.
J Cardiovasc Pharmacol. 2023 May 26. doi: 10.1097/FJC.0000000000001439. PubMedAbstract available
April 2023
HU WS, Lin CL Association of heart failure patients with and without sacubitril-valsartan use
with incident cancer risk.
J Cardiovasc Pharmacol. 2023 Apr 28. doi: 10.1097/FJC.0000000000001433. PubMedAbstract available
NAKATANI D, Dohi T, Hikoso S, Tanaka A, et al Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and
Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results
from the CANDLE trial.
J Cardiovasc Pharmacol. 2023 Apr 18. doi: 10.1097/FJC.0000000000001430. PubMedAbstract available
March 2023
ZHANG H, Huetteman AT, Reyes EA, Appelbaum JS, et al Effects of sacubitril-valsartan in Patients with Various Types of Heart Failure:
A Meta-Analysis.
J Cardiovasc Pharmacol. 2023 Mar 31. doi: 10.1097/FJC.0000000000001421. PubMedAbstract available
KUANG N, Shu B, Yang F, Li S, et al TRAIL or TRAIL-R2 as a predictive biomarker for mortality or cardiovascular
events: A systematic review and meta-analysis.
J Cardiovasc Pharmacol. 2023 Mar 9. doi: 10.1097/FJC.0000000000001415. PubMedAbstract available